

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Supplementary Announcement

Explanation on Regulatory Status and Business Progress of the Dual-Platform Solution for Nipah Virus Detection

Reference is made to the voluntary announcement (the “**Original Announcement**”) of ETHK Labs Inc. (the “**Company**” or “**ETHK Labs**”) issued on 27 January 2026, in relation to the progress regarding the successful development of a dual-platform solution for Nipah virus detection by a subsidiary and the Group’s AI healthcare strategy upgrade. The Board of the Company hereby provides the following supplementary explanation regarding the technical pathways and market application details mentioned in the Original Announcement, to further enhance information transparency and facilitate investors’ comprehensive understanding of the current status and development rationale of the Group’s relevant businesses.

I. REGULATORY CLASSIFICATION AND APPLICATION SCENARIOS FOR THE DUAL-PLATFORM SOLUTION FOR NIPAH VIRUS DETECTION

The dual-platform solution for Nipah virus detection developed by our subsidiary, Shenzhen ICXIVD Biotechnology Co., Ltd. (深圳碳華生物技術有限公司) (“**ICXIVD**”), encompasses the following two technical pathways, each with distinct regulatory attributes and commercial advancement strategies:

1. Intelligent Fluorescent PCR Nucleic Acid Detection Kit

- **Current regulatory designation: This product is currently defined as Research Use Only (“RUO”) within Chinese Mainland.**

- **Registration pathway and current status:** This RUO product is primarily intended for qualified professional institutions such as customs authorities and disease control centres. Such institutions may utilise this product in performing their statutory monitoring and screening duties based on their internal quality control systems and technical validation procedures. According to regulations of the China National Medical Products Administration (NMPA), if the product is intended for future clinical use in hospitals as an in vitro diagnostic reagent, it must apply for and obtain a Class III medical device registration certificate. As no cases of Nipah virus infection have been reported in Chinese Mainland to date, the conditions for conducting the clinical trials required for registration are currently unavailable. Therefore, ICXIVD has not initiated the NMPA Class III medical device registration application process for this product at this stage and has no established timeline for submission.
- **Current application scenarios:** Under the current regulatory framework, such use does not require the product to possess an NMPA registration certificate.

2. **Metagenomic Next-Generation Sequencing (mNGS) Testing Services**

- **Service delivery model:** This service is currently primarily delivered through the Laboratory Developed Test (“LDT”) model.
- **Regulatory environment and business operations:** Since 2022, ICXIVD has continuously provided such LDT testing services to clinicians through methods such as jointly building laboratories with cooperative medical institutions and accepting commissioned testing from third-party medical testing institutions. This business model operates normally under existing regulatory policies and does not currently involve applying for an NMPA medical device registration certificate.

II. **BUSINESS PROGRESS AND TECHNOLOGY MATURITY EXPLANATION**

- mNGS testing services have become a mature business line for ICXIVD, continuously serving the market with complete sample processing, high-throughput sequencing, and intelligent analysis closed-loop capabilities;
- The prototype of the Fluorescent PCR Kit (RUO) has been developed. Its mass production scale and deployment schedule will be dynamically adjusted based on actual order requirements from clients such as customs and disease control agencies.

III. TECHNICAL FOUNDATION AND ECOSYSTEM SYNERGY: THE CAPABILITIES UNDERPINNING RAPID RESPONSE

The efficient rollout of Nipah virus detection solution not only demonstrates ICXIVD's agile R&D capabilities in molecular diagnostics but also highlights the tangible results of the "AI-driven public health intelligence defense" strategy of ETHK Labs. ICXIVD was established through a strategic investment by the Company and iCarbonX, a biotech unicorn enterprise. Its core team possesses extensive expertise in genomics, bioinformatics, and AI algorithms. Its independently developed AI primer design platform and localised database covering over 18,000 pathogens enable the rapid completion of the entire process—from sequence analysis to reagent optimisation—for novel pathogen detection solutions within an extremely short timeframe.

With the steady progress of our acquisition of B-Soft Co., Ltd. (300451.SZ), the Group is accelerating the integration of its multi-dimensional resource capabilities encompassing "healthcare informatisation + IVD distribution network + AI ecosystem". In the future, ICXIVD's testing capabilities are expected to deeply integrate with B-Soft's BsoftGPT medical big model and syndrome monitoring system, which covers nearly 7,000 medical institutions nationwide. This integration will enable a leap from "passive detection" to a closed-loop system of "proactive early warning – precise diagnosis – intelligent intervention". Such technological synergy forms the core foundation for ETHK Labs' construction of the next-generation public health resilience system.

ETHK Labs firmly believes that the core of responding to emerging infectious diseases like Nipah virus lies in building a sustainable, rapidly adaptable systemic technological capability. The Company will continue to leverage its three strategic pillars, K1 (IVD distribution network), K2 (ETHK ecosystem) and K3 (capital operations), to deepen technological integration and ecosystem synergy. It is committed to becoming a reliable technology partner in global public health security, contributing corporate strength to the "Healthy China" initiative.

IV. RISK DISCLOSURE

Investors should note that market demand for relevant testing products is subject to the evolution of the pandemic, policy direction, and changes in the regulatory environment. Furthermore, if the fluorescent PCR kit intends to enter the hospital clinical market in the future, NMPA registration will still be required. The Company will continue to assess relevant risks and strictly comply with the Listing Rules to fulfill its disclosure obligations.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company and to take note of the risk factors set out in the Original Announcement and this announcement.

By order of the Board
ETHK Labs Inc.
Lin Xianya
Executive Director

Hong Kong, 4 March 2026

As at the date of this announcement, the Board comprises two executive directors, namely, Mr. Lin Xianya and Mr. Chan Siu Kei Ken, two nonexecutive directors, namely, Ms. Yao Haiyun and Mr. Liu Fei and three independent nonexecutive directors, namely, Dr. Zhong Renqian, Mr. Xu Da and Mr. Zhang Jianlei.